Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D- aspartate receptor encephalitis: Distinct pattern of disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 7, 2012, Pages 681-686

  Leypoldt, Frank ^a   Buchert, Ralph ^b   Kleiter, Ingo ^c   Marienhagen, Jörg ^d   Gelderblom, Mathias ^a   Magnus, Tim ^a   Dalmau, Josep ^e   Gerloff, Christian ^a   Lewerenz, Jan ^f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FLUORODEOXYGLUCOSE F 18; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENCEPHALITIS; FEMALE; FRONTAL LOBE; GLUCOSE METABOLISM; HUMAN; LONGITUDINAL STUDY; MALE; OCCIPITAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE; WHOLE BODY TOMOGRAPHY;

EID: 84861913867     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-301969     Document Type: Article

References (38)

1. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
2. Prüss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75:1735-9.
3. Granerod J, Ambrose HE, Davies NW, et al UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010;10:835-44.
4. Maeder-Ingvar M, Prior JO, Irani SR, et al. FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry 2010;32:235-6.
5. Mohr BC, Minoshima S. F-18 fluorodeoxyglucose PET/CT findings in a case of anti- NMDA receptor encephalitis. Clin Nucl Med 2010;35:461-3.
6. Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008;70:504-11. (Pubitemid 351653374)
7. Greiner H, Leach JL, Lee KH, et al. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. Seizure 2011;20:266-70.
8. Naeije G, de Hemptinne Q, Depondt C, et al. Acute behavioural change in a young woman evolving towards cerebellar syndrome. Clin Neurol Neurosurg 2010;112:509-11.
9. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655-67.
10. Wandinger KP, Saschenbrecker S, Stoecker W, et al. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011;231:86-91.
11. Van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
12. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical Parametric Maps in Functional imaging: a General Linear Approach. Hum Brain Mapp 1995;2:189-210. (Pubitemid 124008664)
13. Maldjian JA, Laurienti PJ, Burdette JH. Precentral gyrus discrepancy in electronic versions of the Talairach atlas. Neuroimage 2004;21:450-5. (Pubitemid 38115035)
14. Apostolova I, Lindenau M, Fiehler J, et al. Detection of a possible epilepsy focus in a preoperated patient by perfusion SPECT and computer-aided subtraction analysis. Nuklearmedizin 2008;47:N65-8.
15. Rorden C, Bonilha L, Nichols TE. Rank-order versus mean based statistics for neuroimaging. Neuroimage 2007;35:1531-7. (Pubitemid 46561348)
16. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005;128:1764-77. (Pubitemid 41373648)
17. Dadparvar S, Anderson GS, Bhargava P, et al. Paraneoplastic encephalitis associated with cystic teratoma is detected by fluorodeoxyglucose positron emission tomography with negative magnetic resonance image findings. Clin Nucl Med 2003;28:893-6. (Pubitemid 38281847)
18. Pillai SC, Gill D, Webster R, et al. Cortical hypometabolism demonstrated by PET in relapsing NMDA receptor encephalitis. Pediatr Neurol 2010;43:217-20.
19. Fauser S, Talazko J, Wagner K, et al. FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand 2005;111:338-43. (Pubitemid 40559411)
20. Gast H, Schindler K, Z'graggen WJ, et al. Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy. Epilepsy Behav 2010;17:555-7.
21. Chatzikonstantinou A, Szabo K, Ottomeyer C, et al. Successive affection of bilateral temporomesial structures in a case of non-paraneoplastic limbic encephalitis demonstrated by serial MRI and FDG-PET. J Neurol 2009;256:1753-5.
22. Scheid R, Lincke T, Voltz R, et al. Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 2004;61:1785-9. (Pubitemid 39463437)
23. Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008;10:131-7.
24. Weiner SM, Otte A, Schumacher M. Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus. Lupus 2000;9:386-9. (Pubitemid 30389044)
25. Krakauer M, Law I. FDG-PET brain imaging in neuropsychiatric systemic lupus erythematosis with choreic symptoms. Clin Nucl Med 2009;34:122-3.
26. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-75.
27. Tüzün E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009;118:737-43.
28. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481-94. (Pubitemid 30420947)
29. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011;77:589-93.
30. Stone JM. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des 2009;15:2594-602.
31. Grunze HC, Rainnie DG, Hasselmo ME, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996;16:2034-43. (Pubitemid 26144016)
32. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 2009;60:279-86.
33. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 1997;86:903-17. (Pubitemid 27174731)
34. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214. (Pubitemid 24081509)
35. Vollenweider FX, Leenders KL, Scharfetter C, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997;7:9-24. (Pubitemid 27139716)
36. Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997;7:25-38. (Pubitemid 27139717)
37. Hammer RP, Herkenham M, Pert CB, et al. Correlation of regional brain metabolism with receptor localization during ketamine anesthesia: combined autoradiographic 2-[3H]deoxy- D-glucose receptor binding technique. Proc Natl Acad Sci U S A 1982;79:3067-70. (Pubitemid 12058618)
38. Weissman AD, Dam M, London ED. Alterations in local glucose utilization induced by phencyclidine. Brain Res 1987;435:29-40. (Pubitemid 18009769)